Regentaduo Tablet 2.5/1000 mg
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
MFDS item code 201905456 · Approved 2019.07.31
This product's status changed to Expired on 2024.07.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in adults with type 2 diabetes
This medication is used to help control blood sugar levels in adults with type 2 diabetes. It is particularly administered to patients who are receiving drug therapy for the first time or who find it difficult to control their blood sugar levels with monotherapy. It also assists in improving blood sugar control when used in combination with metformin or other diabetes medications. This medication is designed to effectively manage blood sugar according to various treatment regimens presented, thereby maintaining blood sugar levels more stable and improving diabetes management.
The dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). 5. Patients whose blood glucose is not adequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose of 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to investigate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this medicine, because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 1. Patients Who Must Not Take This Medicine).
This medication may lead to a serious side effect known as lactic acidosis due to the active ingredient metformin hydrochloride, so caution is warranted. In particular, it should not be administered to patients with hypersensitivity to this medication or those with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis. Patients with severely impaired renal function or those in conditions that could lead to acute renal impairment may also face risks when using this medication. Avoid administering this medication to patients with liver dysfunction or severe gastrointestinal disturbances such as dehydration, vomiting, or diarrhea. It is advisable for pregnant or breastfeeding women not to use this medication, and those planning to conceive should consult a physician. This medication can induce hypoglycemia, so blood sugar should be closely monitored, especially when used together with insulin or sulfonylureas. Due to the risk of lactic acidosis, renal function, liver function, and heart function should be regularly monitored, and medical personnel should be informed immediately if conditions worsen. When undergoing radiographic examinations using iodinated contrast agents, this medication should be temporarily discontinued for a certain period before and after the tests, and can be resumed once renal function is stabilized. This medication should also be temporarily discontinued before and after surgery and should be restarted based on the physician's discretion after recovery. During treatment, acute pancreatitis or skin diseases such as bullous pemphigoid may occur, and if any such symptoms arise, a physician should be informed immediately, and the medication should be discontinued. Long-term use may lead to vitamin B12 deficiency, so regular monitoring of vitamin B12 levels is essential if symptoms occur or risk factors are present. This medication may interact with other drugs, so it is crucial to inform the physician or pharmacist about any other medications being taken. The elderly often experience decreased renal function, necessitating dose adjustments and regular renal function monitoring. The safety and effectiveness of this medication have not been sufficiently confirmed in pediatric patients, so it is advisable not to use it in children. In case of overdose, severe symptoms such as lactic acidosis may occur, requiring immediate medical attention.
Lactic acidosis, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, dermatitis herpetiformis, severe joint pain accompanied by disability, rhabdomyolysis, increased lipase, increased amylase, constipation, epigastric pain, enterocolitis, intestinal obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's-type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, mood disorder, insomnia, depression, bruising, bone contusion, concussion, bone fracture, hand fracture, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, hematuria, hypotension, flushing, hepatic steatosis, cholelithiasis, hearing loss, erectile dysfunction, thyroid goiter, anemia, dizziness, sensory impairment, chest discomfort, weakness, pain, nosebleed, oropharyngeal pain, speech disorder, allergic rhinitis, exertional dyspnea, wet cough, runny nose, lung mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, male-pattern baldness, hyperhidrosis, dermatitis, anxiety, confusional state, nocturia, dermatitis, hypertension
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture, so the bottle must be tightly closed during storage. It is recommended to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature to ensure the efficacy of the medication and prevent deterioration.
Bright pink, oval, biconvex film-coated tablet
60 tablets (10T/PTP*6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kyungdong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.